J&J, Roche lead January's journal-ad numbers; Novartis nabs new approval for Jakavi; Aussie watchdog to appeal Pfizer ruling;

> Johnson & Johnson ($JNJ) spent more than $2.5 million on medical journal advertising in January, putting itself in line to lead pharma's journal-ad pack as it did in 2014; Roche's ($RHHBY) January numbers came in second at $1.5 million. Release

> Novartis ($NVS) won European approval for Jakavi, its JAK inhibitor, to treat adults with polycythemia vera, a rare and incurable blood cancer. Release

> Pfizer's ($PFE) court fight over Lipitor discounting in Australia isn't over yet; the country's consumer watchdog says it will appeal a federal judge's decision that the company hadn't engaged in anticompetitive conduct. Report

> Boehringer Ingelheim is poised to roll out its idiopathic pulmonary fibrosis drug Ofev in Europe, with an on-sale date in Germany this week. Report

> Teva Pharmaceutical Industries ($TEVA) beefed up its oncology pipeline with a deal to buy four of Ignyta's drug candidates and invest in the biotech drug developer. Release

And Finally... A Novo Nordisk ($NVO) documentary about Type 2 diabetes in Ghana is up for a vote in the annual Boston College Center for Corporate Citizenship Film Festival. Report

Suggested Articles

Cardiac risks associated with roxadustat are comparable to placebo in nondialysis patients and to Amgen's standard, Epogen, in those on dialysis.

Pfizer and Merck KGaA's immuno-oncology agent Bavencio failed another gastric cancer study, this time as a maintenance treatment after chemotherapy.

A jury ordered Biogen to pay nearly $6 million to a former sales manager who reported a colleague's misconduct and got fired a few months later.